Pfizer nabs RSV therapeutic biotech ReViral in quick $525M bolt-on Eli Lilly, AbbVie positioned for long-term growth, while Bristol Myers Squibb may struggle: analysts Senate expected to leave for recess without passing $10B COVID package Aidoc locks down FDA OK for brain aneurysm-spotting AI, its 9th agency nod Pfizer rolls out voluntary retirement scheme in India as it dives deeper into digital Takeda spinout HilleVax goes public, a test of the choppy waters for biotechs on Wall Street Viz.AI collects $100M to spot more maladies in emergency CT scans Alnylam founder Maraganore snags $10.2M pay in his farewell year, as new CEO Greenstreet grabs $8.6M Blue Shield of California, Walgreens aim to serve 'healthcare deserts' with new Health Corner locations Jazz, Werewolf to howl at the moon together in $1.26B backloaded biobucks pact Digital health funding boom slows in Q1. Was 2021 the high watermark for investment? C2i Genomics snags European approval for blood test to detect residual cancer Akebia reveals sweeping layoffs and vadadustat partial clinical hold after FDA snub Featured Story | By Annalee Armstrong Pfizer has had plenty of success in respiratory syncytial virus lately, with multiple FDA designations and clinical advancements for its vaccine candidate. But that’s not enough for the pharma giant. Today, the New York-based behemoth is acquiring ReViral and its collection of therapeutics for the pesky respiratory virus for $525 million. read more |
| |
|---|
|
Top Stories By Kevin Dunleavy While Eli Lilly is positioned for growth in the second half of this decade, Bristol Myers Squibb is not, according to a comprehensive look of the industry in the United States from Morgan Stanley. Prospects this decade also are bright for AbbVie, Morgan Stanley says, while the analysts' expectations for Johnson & Johnson, Merck, Pfizer and Organon are tempered. read more By Robert King The Senate has reached a bipartisan deal for $10 billion in additional COVID-19 relief funds but doesn't include any money for global response efforts. read more By Andrea Park Within four years, the Israeli startup has racked up nine nods from the FDA, the latest for an AI tool designed to automatically identify potential cases of brain aneurysm in head CT scans. read more By Fraiser Kansteiner Pfizer, like many other companies during the pandemic, has been quick to embrace the pivot to digital and hybrid work. Now, that remote shift could presage major changes to the drug giant’s workforce overseas. read more By Max Bayer Takeda spinout HilleVax filed for a $100 million IPO Wednesday, a test of the choppy public waters after a bear market tortured biotechs for much of 2021. The company believes its norovirus vaccine candidate could be a winner as it prepares to launch a phase 2 trial in infants. read more By Conor Hale After an FDA clearance earlier this year for its artificial intelligence-powered program designed to spot dangerous aneurysms, Viz.ai raised $100 million to continue expanding into other conditions. The venture capital financing comes after Viz.AI passed the 1,000 mark on hospitals using its AI platform to read and triage CT scans. read more By Angus Liu John Maraganore, Ph.D., officially stepped down as CEO of Alnylam Pharmaceuticals at the end of 2021. In his last year leading the RNA interference specialist, the former helmsman got $10.18 million in total compensation. read more By Paige Minemyer Blue Shield of California is teaming up with Walgreens to launch new Health Corners in 12 of its stores in the San Francisco Bay area and Los Angeles County. If all goes well, the companies plan to use what they learn at this first batch of locations to expand the network and add more services people need. read more By Annalee Armstrong Jazz Pharmaceuticals and Werewolf Therapeutics will work together in a new $15 million upfront, backloaded biobucks deal that covers a preclinical oncology candidate that goes after difficult and unresponsive tumors. read more By Heather Landi The more restrained digital health funding numbers in the first quarter may reflect investor caution, according to the report, with the rise-and-fall of COVID variants, energy shocks, market volatility, the dismal performance of public digital health companies and inflation numbers signaling choppy waters for digital health investors. read more By Andrea Park The C2inform test’s findings can be used not only to detect lasting signs of cancer but also to keep track of its progression and monitor how well various treatments are working. read more By Fraiser Kansteiner After vadadustat's rejection in anemia from chronic kidney disease last month, developer Akebia Therapeutics warned it would need to tighten its belt. Now, the company is disclosing cuts to nearly half of its workforce, and it's revealed a partial clinical hold on studies of its drug in kids. read more |
